These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 22471716)
1. Nanomedicine against multidrug resistance in cancer treatment. Gao J; Feng SS; Guo Y Nanomedicine (Lond); 2012 Apr; 7(4):465-8. PubMed ID: 22471716 [No Abstract] [Full Text] [Related]
2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Shapira A; Livney YD; Broxterman HJ; Assaraf YG Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184 [TBL] [Abstract][Full Text] [Related]
3. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1. Gillet JP; Gottesman MM Drug Resist Updat; 2012; 15(1-2):2-4. PubMed ID: 22465109 [No Abstract] [Full Text] [Related]
4. Multidrug resistance reversal agents. Robert J; Jarry C J Med Chem; 2003 Nov; 46(23):4805-17. PubMed ID: 14584929 [No Abstract] [Full Text] [Related]
5. Cancer chemoprevention by polyphenols and their potential application as nanomedicine. Tabrez S; Priyadarshini M; Urooj M; Shakil S; Ashraf GM; Khan MS; Kamal MA; Alam Q; Jabir NR; Abuzenadah AM; Chaudhary AG; Damanhouri GA J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2013; 31(1):67-98. PubMed ID: 23534395 [TBL] [Abstract][Full Text] [Related]
6. Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age? Bourquin JP; Bornhauser B Expert Rev Hematol; 2010 Aug; 3(4):369-72. PubMed ID: 21083025 [No Abstract] [Full Text] [Related]
8. Obinutuzumab in multidrug-resistant hairy cell leukemia. Bohn JP; Willenbacher E; Steurer M Ann Hematol; 2016 Jan; 95(2):351-2. PubMed ID: 26446506 [No Abstract] [Full Text] [Related]
9. Nanomedicine to overcome cancer multidrug resistance. Yang X; Yi C; Luo N; Gong C Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871 [TBL] [Abstract][Full Text] [Related]
10. A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. Sawicka M; Kalinowska M; Skierski J; Lewandowski W J Pharm Pharmacol; 2004 Sep; 56(9):1067-81. PubMed ID: 15324475 [TBL] [Abstract][Full Text] [Related]
11. The reversal of multidrug resistance: an update. Kellen JA J Exp Ther Oncol; 2003; 3(1):5-13. PubMed ID: 12724854 [No Abstract] [Full Text] [Related]
12. The great multidrug-resistance paradox. Chen VY; Rosania GR ACS Chem Biol; 2006 Jun; 1(5):271-3. PubMed ID: 17163753 [TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance in cancer cells by Rhizoma Alismatis extract. Fong WF; Wang C; Zhu GY; Leung CH; Yang MS; Cheung HY Phytomedicine; 2007 Feb; 14(2-3):160-5. PubMed ID: 16713217 [TBL] [Abstract][Full Text] [Related]
15. Achilles heels and Trojan horses against drug-resistant tumor cells. Park K J Control Release; 2011 Jan; 149(2):91. PubMed ID: 21167115 [No Abstract] [Full Text] [Related]
16. Cancer multidrug resistance-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs. Patanè S Int J Cardiol; 2014 Oct; 176(3):1306-8. PubMed ID: 25131921 [No Abstract] [Full Text] [Related]
17. Synthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents. Schmidt M; Teitge M; Castillo ME; Brandt T; Dobner B; Langner A Arch Pharm (Weinheim); 2008 Oct; 341(10):624-38. PubMed ID: 18816589 [TBL] [Abstract][Full Text] [Related]
18. [Reversal effect and mechanism of lobeline on the multidrug-resistance of human breast cancer cells MCF-7/ADM]. Chen J; Shen L; Zhou R; Yao W; Zhong M; Zhu ZH; Zeng S Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Aug; 34(8):738-43. PubMed ID: 19734580 [TBL] [Abstract][Full Text] [Related]
19. NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer? Friberg S; Nyström AM J Nanobiotechnology; 2016 Mar; 14():17. PubMed ID: 26955956 [TBL] [Abstract][Full Text] [Related]
20. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. O'Connor R; Clynes M; Dowling P; O'Donovan N; O'Driscoll L Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):805-17. PubMed ID: 18028026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]